首页> 外文期刊>Drug Design, Development and Therapy >Asiatic acid ameliorates CC lsub4/sub-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways
【24h】

Asiatic acid ameliorates CC lsub4/sub-induced liver fibrosis in rats: involvement of Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways

机译:亚洲酸改善CC 1 4 诱导的大鼠肝纤维化:Nrf2 / ARE,NF-κB/IκBα和JAK1 / STAT3信号通路的参与

获取原文
获取外文期刊封面目录资料

摘要

Purpose: Currently, there are no effective therapies for liver fibrosis; hence, the development of anti-liver fibrosis agents is urgently needed. Here, we attempted to investigate the therapeutic effect and mechanism of asiatic acid (AA) on liver fibrosis, mainly focusing on the impact of AA on nuclear erythroid 2-related factor 2/antioxidant response element (Nrf2/ARE), nuclear factor-kappa B (NF-κB)/IκBα, and JAK1/signal transducer and activator of transcription 3 (STAT3) signaling pathways. Methods: Rats were induced liver fibrosis by carbon tetrachloride (CCl4) for 6 weeks and concomitantly treated with AA (5 and 15 mg/kg) or vehicle by daily gavage. After AA treatment, the morphology of liver tissue was analyzed by H&E and Masson’s trichrome staining, and serum biochemical indicators were also assayed. Thereafter, the protein levels of Nrf2, HO-1, NQO-1, GCLC, NF-κB, IκBα, JAK1, p-JAK1, STAT3, and p-STAT3 were determined by Western blotting. Results: Our results showed that AA treatment dramatically ameliorated CCl4-induced oxidative stress, inflammation, and fibrosis in rats. The expression of nuclear Nrf2 was increased after AA treatment, whereas cytoplasm Nrf2 levels were decreased. The protein expression of Nrf2 target proteins including HO-1, NQO-1, and GCLC was significantly increased by AA treatment. Furthermore, AA treatment decreased the levels of nuclear NF-κB to inhibit NF-κB/IκBα signaling pathway. In addition, we also found that AA treatment regulated JAK1/STAT3 signaling by decreasing the phosphorylation levels of JAK1 and STAT3. Conclusion: These results demonstrate that AA ameliorates CCl4-induced liver fibrosis in rats by regulating Nrf2/ARE, NF-κB/IκBα, and JAK1/STAT3 signaling pathways, which suggests that AA might be a new antifibrosis agent that improves liver fibrosis.
机译:目的:目前尚无有效的治疗肝纤维化的方法。因此,迫切需要开发抗肝纤维化剂。在这里,我们试图研究积雪草酸(AA)对肝纤维化的治疗作用和机制,主要集中于AA对核红细胞2相关因子2 /抗氧化反应元件(Nrf2 / ARE),核因子κ的影响B(NF-κB)/IκBα,以及JAK1 /信号转导子和转录激活子3(STAT3)信号通路。方法:用四氯化碳(CCl4)诱导大鼠肝纤维化6周,并每日灌胃给予AA(5和15 mg / kg)或运载体。经过AA处理后,通过H&E和Masson的三色染色法分析了肝组织的形态,还测定了血清生化指标。此后,通过蛋白质印迹法测定Nrf2,HO-1,NQO-1,GCLC,NF-κB,IκBα,JAK1,p-JAK1,STAT3和p-STAT3的蛋白水平。结果:我们的结果表明,AA处理可显着改善CCl4诱导的大鼠氧化应激,炎症和纤维化。 AA处理后,核Nrf2的表达增加,而细胞质Nrf2的水平降低。通过AA处理,Nrf2靶蛋白(包括HO-1,NQO-1和GCLC)的蛋白表达显着增加。此外,AA治疗降低了核NF-κB的水平,以抑制NF-κB/IκBα信号通路。此外,我们还发现AA处理通过降低JAK1和STAT3的磷酸化水平来调节JAK1 / STAT3信号传导。结论:这些结果表明,AA通过调节Nrf2 / ARE,NF-κB/IκBα和JAK1 / STAT3信号通路改善了CCl4诱导的大鼠肝纤维化,这表明AA可能是一种改善肝纤维化的新型抗纤维化药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号